Thomas Eldridge Stinchcombe, MD
Osimertinib (Tagrisso) and alectinib (Alecensa) are 2 new frontline therapies for patients with non–small cell lung cancer (NSCLC) that have demonstrated tremendous advancements for targeted therapy, said Thomas E. Stinchcombe, MD.
State of the Science Summit™ on Non–Small Cell Lung Cancer, Stinchcombe, a professor in the Division of Medical Oncology at Duke University and member of Duke Cancer Institute, discussed existing and emerging first-line regimens coming through the pipeline for the treatment of patients with NSCLC.
OncLive®: What are your thoughts on osimertinib and alectinib as first-line treatments for patients with NSCLC?
: There have been tremendous advances with targeted therapy in the last year. A phase III trial compared osimertinib with erlotinib and gefitinib. This revealed an improved PFS with a median of 18.9 months [with osimertinib], which also demonstrated lower grade 3/4 toxicities.
... to read the full story